A year in the life of the EU-CardioRNA COST Action: CA17129 catalysing transcriptomics research in cardiovascular disease.

  • Cardiovascular Research Unit
  • Integrated BioBank of Luxembourg
May 18, 2020 By:
  • Robinson EL
  • Gomes C
  • Potočnjak I
  • Hellemans J
  • Betsou F
  • de Gonzalo-Calvo D
  • Stoll M
  • Yilmaz MB
  • Ágg B
  • Beis D
  • Carmo-Fonseca M
  • Enguita FJ
  • Dogan S
  • Tuna BG
  • Schroen B
  • Ammerlaan W
  • Kuster GM
  • Carpusca I
  • Pedrazzini T
  • Emanueli C
  • Martelli F
  • Devaux Y.

The EU-CardioRNA Cooperation in Science and Technology (COST) Action is a European-wide consortium established in 2018 with 31 European country members and four associate member countries to build bridges between translational researchers from academia and industry who conduct research on non-coding RNAs, cardiovascular diseases and similar research areas. EU-CardioRNA comprises four core working groups (WG1-4). In the first year since its launch, EU-CardioRNA met biannually to exchange and discuss recent findings in related fields of scientific research, with scientific sessions broadly divided up according to WG. These meetings are also an opportunity to establish interdisciplinary discussion groups, brainstorm ideas and make plans to apply for joint research grants and conduct other scientific activities, including knowledge transfer. Following its launch in Brussels in 2018, three WG meetings have taken place. The first of these in Lisbon, Portugal, the second in Istanbul, Turkey, and the most recent in Maastricht, The Netherlands. Each meeting includes a scientific session from each WG. This meeting report briefly describes the highlights and key take-home messages from each WG session in this first successful year of the EU-CardioRNA COST Action.

2020 May. Noncoding RNA.6(2).
Other information